Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00603278 · ClinicalTrials.gov registry record · Phase 2

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

A Phase 2 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
622
Enrollment target

NCT00603278 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 622 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00603278, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
622 participants
Enrollment target

Study Summary

This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.

Interventions

  • DRUG placebo
  • DRUG GW685698X

Trial Details

FieldValue
Enrollment Target 622 participants
Start Date 2007-12
Est. Completion 2008-11
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT00603278

The ClinicalTrials.gov registry entry for NCT00603278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 622 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00603278 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00603278 about?

NCT00603278 is a clinical study titled "A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.". This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.

What is the current status of trial NCT00603278?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 622 participants. The study started on 2007-12. Estimated completion is 2008-11.

What interventions are being tested in trial NCT00603278?

The interventions under investigation include: placebo (DRUG), GW685698X (DRUG).

Who is sponsoring clinical trial NCT00603278?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.